Biotechnology Vaccine Platform Regulation In Russia.

1. Introduction

Biotechnology vaccine platform regulation in Russia concerns the legal framework governing the research, development, manufacture, clinical testing, registration, distribution, storage, safety monitoring and commercialization of vaccines developed through modern biotechnology.

A vaccine platform is the technological method used to develop and deliver an antigen or genetic instructions that stimulate an immune response. Major platforms include:

Viral-vector vaccines – use modified viruses to deliver genetic instructions.

mRNA vaccines – use messenger RNA to instruct cells to produce an antigen.

DNA vaccines – use DNA-based genetic instructions.

Recombinant protein vaccines – use genetically engineered proteins.

Inactivated vaccines – contain pathogens rendered non-infectious.

Live attenuated vaccines – use weakened microorganisms.

Virus-like particle vaccines – use particles that resemble viruses but do not contain infectious genetic material.

Russia regulates these technologies through pharmaceutical legislation, public-health legislation, biotechnology and sanitary regulations, clinical-trial requirements, intellectual-property law and product-liability principles.

The central objective is to balance scientific innovation, public-health protection, patient rights, vaccine accessibility and pharmaceutical manufacturing standards.

An important distinction is that Russia generally regulates vaccines through the legal framework for medicinal products and immunobiological medicinal products rather than creating an entirely separate statutory licensing system for every vaccine platform.

2. Constitutional and Legislative Framework

A. Constitution of the Russian Federation

The Constitution provides the fundamental legal foundation for vaccine regulation.

Important provisions include:

Article 20: Protection of the right to life.

Article 21: Protection of human dignity and prohibition of treatment that violates human dignity.

Article 41: Right to health protection and medical assistance.

Article 44: Protection of intellectual property.

Article 55: Conditions under which federal law may restrict constitutional rights.

Article 41 is particularly important because vaccine development and immunization policies are connected with the state's constitutional responsibility to protect public health.

However, public-health objectives must be reconciled with individual rights, informed consent and lawful medical procedures.

B. Federal Law No. 61-FZ of 12 April 2010 – On Circulation of Medicines

This is the principal legislation governing vaccine products in Russia.

The law regulates:

Pharmaceutical development.

Preclinical research.

Clinical investigations.

State registration of medicinal products.

Manufacturing and quality control.

Pharmaceutical distribution.

Pharmacovigilance.

Post-registration safety monitoring.

Vaccines are subject to requirements applicable to medicinal products, with additional considerations arising from their biological and immunological characteristics.

The registration process examines matters such as quality, safety and efficacy.

A new vaccine platform does not automatically receive marketing authorization merely because its underlying technology has been approved or used elsewhere.

C. Federal Law No. 157-FZ of 17 September 1998 – On Immunoprophylaxis of Infectious Diseases

This legislation establishes the principal legal framework for preventive vaccination.

It addresses:

National immunization policy.

Preventive vaccination.

Vaccine availability.

Vaccine safety.

Medical contraindications.

Citizens' rights and responsibilities.

State oversight of immunoprophylaxis.

The law is particularly significant because it connects biotechnology vaccine development with public-health implementation.

D. Federal Law No. 323-FZ of 21 November 2011 – On the Fundamentals of Health Protection of Citizens

This law regulates medical treatment, patient rights and informed consent.

Article 20 is especially relevant to vaccination because it establishes the general framework for informed voluntary consent to medical intervention and refusal of medical intervention.

Accordingly, the existence of a government vaccination programme does not eliminate the need to comply with applicable consent requirements.

E. Federal Law No. 52-FZ of 30 March 1999 – On the Sanitary and Epidemiological Well-Being of the Population

This law establishes sanitary and epidemiological requirements relating to infectious diseases, disease prevention and public-health protection.

It supports government measures concerning:

Epidemiological surveillance.

Infectious disease prevention.

Sanitary controls.

Public-health emergency responses.

Protection against biological risks.

F. Eurasian Economic Union (EAEU) Pharmaceutical Regulations

Russia is a member of the Eurasian Economic Union. Its pharmaceutical market is therefore influenced by common EAEU rules.

The EAEU framework covers:

Common medicinal-product registration procedures.

Good Manufacturing Practice (GMP).

Good Clinical Practice (GCP).

Quality-control standards.

Pharmacovigilance.

Regulatory recognition between member states.

The EAEU pharmaceutical framework is particularly important for biotechnology vaccines because biological products can involve complex manufacturing processes and specialized quality-control requirements.

The transition to common EAEU pharmaceutical registration rules has also affected the registration of Russian-developed vaccines.

ICLRC+1

 

3. Regulatory Authorities Responsible for Vaccine Platforms

Several Russian authorities have responsibilities relating to biotechnology vaccine regulation.

AuthorityPrincipal responsibility
Ministry of HealthPharmaceutical policy and registration framework
Ministry of Industry and TradeIndustrial and pharmaceutical manufacturing policy
RoszdravnadzorMedicinal-product quality and safety supervision
RospotrebnadzorSanitary and epidemiological protection
State Research Centre VectorScientific and vaccine research activities
Gamaleya National Research CentreVaccine research and development

The responsibilities of research institutions should be distinguished from those of regulatory authorities. A research institution developing a vaccine does not thereby acquire the authority to grant its own marketing authorization.

4. Regulation of Different Vaccine Platforms

A. Viral-Vector Vaccine Regulation

Как работает вакцина от коронавируса Спутник V

 

 

Analysis: How the puzzle of viral vector vaccines was solved, leading to today's COVID-19 shots - McMaster News

 

 

Immune Response Induced by Adenoviral Vector Vaccines | BioRender Science Templates

 

8

 

Viral-vector vaccines use modified viruses to transport genetic material into human cells.

A prominent Russian example is Sputnik V.

Its development involved adenovirus-based vectors, including Ad26 and Ad5.

Legal issues include:

Biological safety of the vector.

Genetic stability.

Manufacturing consistency.

Potential adverse immune reactions.

Clinical-trial reliability.

Long-term safety surveillance.

Product liability.

The regulatory authority must consider whether the vector is sufficiently characterized and whether the vaccine's manufacturing process consistently produces a product meeting the required quality standards.

B. mRNA Vaccine Regulation

Vaccines - a beacon of hope in the fight against pandemics - Healthcare industry

 

 

mRNA vaccines for infectious diseases: principles, delivery and clinical translation | Nature Reviews Drug Discovery

 

 

Lipid Nanoparticle Mediated mRNA Vaccine Delivery | BioRender Science Templates

 

8

 

mRNA vaccines use messenger RNA enclosed in delivery systems, commonly lipid nanoparticles.

Their regulatory assessment raises questions concerning:

RNA sequence integrity.

Purity and potency.

Lipid nanoparticle composition.

Stability and storage conditions.

Delivery efficiency.

Immunogenicity.

Potential inflammatory reactions.

Russian pharmaceutical legislation does not create a completely independent registration category simply because a vaccine uses mRNA technology.

Instead, the product must satisfy the applicable medicinal-product registration and biological-product quality requirements.

C. Recombinant Protein Vaccines

Nuvaxovid-Impfstoff vor Zulassung: Das Vakzin, auf das manche Ungeimpfte warten | heise online

 

 

heise.de

Recombinant protein vaccines use proteins produced through genetic engineering.

A Russian example is EpiVacCorona.

The relevant legal requirements include:

Characterization of the antigen.

Protein purity.

Production-cell-line controls.

Adjuvant safety.

Batch consistency.

Immunogenicity testing.

Clinical evidence of efficacy.

D. Inactivated Vaccine Platforms

COVID-19 Vaccines, Effectiveness, and Immune Responses

 

 

mdpi.com

Inactivated vaccines use microorganisms that have been rendered non-infectious.

For these vaccines, regulatory assessment focuses on:

Complete inactivation.

Absence of residual infectious agents.

Antigen integrity.

Manufacturing controls.

Sterility.

Batch-release testing.

E. Live Attenuated Vaccine Platforms

Live attenuated vaccines use weakened microorganisms.

Their regulation requires particular attention to:

Genetic stability.

Reversion-to-virulence risks.

Shedding.

Environmental exposure.

Contraindications.

Special precautions for immunocompromised individuals.

The manufacturer must establish that the vaccine's benefits justify the risks associated with the use of live biological material.

5. Clinical Trials and Vaccine Platform Approval

Clinical testing is one of the most important stages of vaccine regulation.

Under Federal Law No. 61-FZ, clinical investigations of medicinal products for medical use are governed by the statutory requirements concerning clinical trials.

Article 38 addresses clinical investigations, including the assessment of vaccine dosage, vaccination schedules, safety and prophylactic efficacy.

The general clinical-development process includes:

Stage 1: Preclinical studies

Laboratory and appropriate non-clinical studies examine toxicity, biological activity and other relevant risks.

Stage 2: Early clinical investigations

Initial human studies examine safety, tolerability and appropriate dosage.

Stage 3: Expanded clinical investigations

Larger studies assess safety and the ability of the vaccine to produce an immune response.

Stage 4: Confirmatory efficacy assessment

Clinical evidence is evaluated to determine whether the vaccine prevents the targeted disease or produces another legally approved clinical benefit.

Stage 5: Post-registration monitoring

The manufacturer and relevant authorities monitor adverse reactions, manufacturing changes and emerging safety information.

Importantly, immunogenicity is not automatically equivalent to demonstrated clinical efficacy. A vaccine's ability to produce antibodies does not, by itself, establish the full extent of its protection against disease.

WIPO+1

6. Emergency Registration and Accelerated Vaccine Approval

Emergency circumstances can create pressure to make vaccines available rapidly.

Russia's COVID-19 vaccine experience demonstrates the importance of distinguishing ordinary registration from special or accelerated regulatory arrangements.

The Sputnik V registration in August 2020 attracted international attention because it occurred before the completion of the large-scale Phase III clinical programme.

This raised important questions concerning:

The adequacy of clinical evidence.

The balance between speed and safety.

Transparency of clinical-trial results.

Regulatory accountability.

Post-registration monitoring.

Emergency authorization does not eliminate the underlying requirement to assess product quality, safety and efficacy.

A particularly important legal issue is whether an accelerated approval mechanism has a sufficiently clear statutory basis and provides adequate safeguards for patients.

7. Manufacturing, GMP and Quality Control

Biotechnology vaccine manufacturing requires specialized regulatory supervision.

The manufacturing process may involve genetically modified organisms, cell cultures, viral vectors, recombinant proteins and sophisticated purification technologies.

Important controls include:

Raw-material qualification.

Cell-bank characterization.

Biological containment.

Sterility testing.

Endotoxin testing.

Potency testing.

Batch consistency.

Contamination prevention.

Cold-chain management.

Manufacturing documentation.

A manufacturing defect can create legal responsibility even where the original vaccine platform has been scientifically validated.

For example, a vaccine may have an acceptable research profile but still fail to satisfy quality requirements if a particular production batch is contaminated or incorrectly stored.

The EAEU GMP and pharmacovigilance framework provides an important regional compliance structure.

pharmacopoeia.ru+1

 

8. Important Russian Case Laws Relating to Vaccine Regulation

An important limitation in Russian vaccine jurisprudence is that reported judicial decisions have concentrated more heavily on compulsory vaccination, informed consent, employment consequences and public-health powers than on the technical patentability or classification of individual vaccine platforms.

The following decisions are therefore relevant to vaccine-platform regulation, although they should not all be described as direct disputes over vaccine technology.

Case 1. Constitutional Court of the Russian Federation – 21 November 2013, No. 1867-O

Important constitutional precedent

Subject: Preventive vaccination and employment restrictions.

The Constitutional Court considered the legal consequences of refusing preventive vaccination in work involving a heightened risk of infectious disease.

The relevant legal principle is that statutory vaccination requirements may have employment consequences where the work creates particular infectious-disease risks.

Legal significance:

Public-health protection can justify certain employment restrictions.

Vaccination requirements must have a legal basis.

Restrictions must operate within the applicable statutory framework.

The protection of other individuals is relevant when balancing individual rights and public health.

Application to biotechnology: A person challenging a vaccination-related employment restriction may raise questions about the vaccine's safety, legal authorization and applicable medical contraindications. However, the constitutional principle does not independently establish that every vaccine platform is safe or effective.

Case 2. Fifth Appellate Court – 28 October 2021, No. 66a-1235/2021

Subject: Compulsory COVID-19 vaccination and employment-related rights.

The court examined a challenge concerning regional vaccination requirements for employees working in service-related activities.

The court concluded that the regional measure was consistent with higher-ranking legislation. It also emphasized that the measure did not remove the statutory possibility of obtaining a medical exemption or refusing medical intervention under the applicable health-protection legislation.

Legal significance:

Public-health authorities may impose vaccination requirements for designated occupational categories under applicable legislation.

Medical exemptions remain relevant.

The statutory right to refuse medical intervention must be considered.

A distinction exists between a vaccination requirement and the physical administration of a vaccine without consent.

Application: The case is relevant to the legal implementation of biotechnology vaccine programmes and the relationship between public-health requirements and individual autonomy.

Covid-19 Litigation

 

Case 3. Tula Regional Court – 15 December 2021, No. 33-4126/2021

Subject: Suspension of employees who refused COVID-19 vaccination.

The court considered employment disputes arising from the failure of employees to undergo vaccination during the COVID-19 emergency.

The court upheld the employment-related consequences in the circumstances of the case.

It considered the protection of the health and life of other members of the workplace community.

Legal significance:

Occupational vaccination requirements can produce temporary employment consequences.

Public-health protection is a relevant justification.

Individual employment rights must be assessed against applicable infectious-disease legislation.

Application: The case illustrates how vaccines developed using new biotechnology platforms can become part of legally enforceable public-health programmes.

Covid-19 Litigation

 

Case 4. Eighth Cassation Court of General Jurisdiction – 6 October 2022

Case: No. 8G-17466/2022 (88-18098/2022).

Subject: COVID-19 vaccination and suspension of a healthcare employee.

The dispute concerned a medical employee who had not provided proof of vaccination or an appropriate medical contraindication.

The court upheld the rejection of the employee's claims after considering the applicable federal and regional vaccination requirements.

Legal significance:

Healthcare employment can involve specific infectious-disease obligations.

Employers must act within the statutory framework.

Medical contraindications must be considered.

Suspension from work may be justified where the applicable legal conditions are satisfied.

Application: This decision is relevant to the regulatory consequences of vaccine implementation in healthcare institutions.

ГАРАНТ

 

Case 5. Second Cassation Court of General Jurisdiction – 13 December 2022

Case: No. 8G-31504/2022 (88-29379/2022).

Subject: Employment suspension following refusal of COVID-19 vaccination.

The dispute involved workers at a museum who were subject to a regional vaccination requirement.

The courts found that the relevant employees belonged to a category covered by the applicable regional public-health measure and had not established a relevant medical exemption.

Legal significance:

Regional sanitary requirements can apply to designated occupational categories.

Employers must establish the applicability of the relevant requirement.

Proper notification and compliance with employment procedures matter.

Application: The case demonstrates how vaccine policy is translated into workplace compliance obligations.

ГАРАНТ

 

Case 6. Constitutional Court – 31 October 2023, No. 2759-O

Important constitutional interpretation

Subject: Constitutional challenges to compulsory vaccination-related employment consequences.

The Constitutional Court examined arguments concerning the suspension of employees who had not received preventive vaccination against COVID-19.

It considered the relationship between:

Article 41 of the Constitution.

Article 5 of Federal Law No. 157-FZ.

Article 76 of the Labour Code.

The sanitary and epidemiological legislation.

The Court maintained that the relevant legal provisions formed part of a mechanism for preventing risks to public health and protecting individuals from infectious diseases.

Legal significance:

The decision supports the constitutional validity of legally established employment consequences for certain categories of unvaccinated workers.

It does not, however, mean that vaccination can be administered without the consent required under applicable medical-intervention legislation.

Application: It is relevant to the constitutional framework governing the deployment of newly developed vaccines.

Контур.Норматив

 

Case 7. Constitutional Court – 26 September 2024, No. 2187-O

Subject: COVID-19 vaccination and employment restrictions in the energy sector.

The applicant challenged the consequences of refusing vaccination under regional epidemiological requirements.

The Constitutional Court considered the statutory basis for employment suspension where workers belonged to categories subject to vaccination requirements.

Legal significance:

The Court maintained the relationship between:

Preventive vaccination legislation.

Sanitary and epidemiological powers.

Labour-law suspension provisions.

Protection of public health and workplace safety.

Application: The decision illustrates that vaccine deployment can have consequences extending beyond hospitals and directly affecting industrial sectors.

Контур.Норматив

 

Case 8. Constitutional Court – 28 January 2025, No. 83-O

Subject: Refusal of preventive vaccination and suspension from employment.

The applicant challenged the constitutional implications of being suspended without salary after refusing a COVID-19 vaccination required under applicable regional measures.

The Court declined to accept the constitutional complaint for consideration, referring to the existing statutory framework governing high-risk employment and preventive vaccination.

Legal significance:

The decision reinforces the importance of the statutory relationship between occupational risk, vaccination requirements and employment suspension.

It should not be interpreted as a judicial determination that every individual vaccine is free from adverse effects or that every employment suspension is automatically lawful.

Application: It provides more recent constitutional guidance concerning the implementation of vaccination requirements.

ГАРАНТ

 

Case-law summary

DecisionPrincipal legal issue
Constitutional Court, 1867-O (2013)Vaccination and occupational risk
Fifth Appellate Court, 66a-1235/2021Regional vaccination requirements
Tula Regional Court, 33-4126/2021Employment suspension
Eighth Cassation Court, 8G-17466/2022Healthcare worker vaccination
Second Cassation Court, 8G-31504/2022Workplace vaccination compliance
Constitutional Court, 2759-O (2023)Constitutional validity of suspension
Constitutional Court, 2187-O (2024)Vaccination and energy-sector employment
Constitutional Court, 83-O (2025)Refusal and employment consequences

Important research qualification: These are relevant vaccination and public-health decisions, not reported judgments establishing a comprehensive judicial doctrine specifically for mRNA, viral-vector or recombinant-protein vaccine platforms. The distinction is important in academic legal writing.

9. Vaccine Platform Intellectual Property Rights

Intellectual-property protection is another important part of Russian biotechnology vaccine regulation.

The principal legislation is Part IV of the Civil Code of the Russian Federation.

It provides protection for qualifying inventions, utility models, industrial designs, trademarks and other intellectual-property interests.

A. Patent protection

Patent protection may apply to:

Novel vaccine compositions.

Novel delivery systems.

Manufacturing processes.

Recombinant protein technologies.

Novel adjuvant formulations.

Certain methods of producing biological products.

However, a naturally occurring biological substance or discovery is not automatically patentable.

The invention must satisfy the relevant legal requirements, including novelty, inventive step and industrial applicability.

B. Vaccine manufacturing trade secrets

Vaccine manufacturers may also protect confidential technical information, including:

Production formulas.

Purification techniques.

Cell-culture processes.

Manufacturing parameters.

Quality-control procedures.

Trade-secret protection is important because biotechnology manufacturing frequently depends on confidential technical know-how beyond what a patent discloses.

C. Patent disputes and compulsory licensing

Vaccine development may involve disputes concerning patent ownership, licensing, manufacturing rights and technology transfer.

Russian law provides mechanisms for certain uses of patented inventions without the patent holder's consent, subject to statutory conditions and compensation requirements.

Such mechanisms must not be confused with an unrestricted right to copy another company's vaccine technology.

10. Vaccine Safety, Pharmacovigilance and Product Liability

The regulatory responsibility does not end after vaccine registration.

Post-registration monitoring is necessary because some adverse reactions may become apparent only after a vaccine has been administered to a large population.

Important legal issues include:

A. Adverse-event reporting

Healthcare organizations and relevant pharmaceutical actors must comply with applicable adverse-reaction reporting and pharmacovigilance requirements.

B. Product quality

Manufacturers may face regulatory consequences if a vaccine fails to satisfy applicable quality specifications.

C. Manufacturing negligence

Liability may arise from contamination, incorrect storage, defective production processes or inadequate quality control.

D. Patient injury

Depending on the facts and applicable legal provisions, civil compensation, consumer-protection remedies and other legal mechanisms may become relevant.

E. Regulatory accountability

Regulatory authorities must exercise their statutory functions in accordance with applicable administrative and pharmaceutical legislation.

A critical distinction must be maintained between an adverse event occurring after vaccination and an adverse reaction scientifically attributable to the vaccine. Causation requires appropriate evidence.

11. Ethical and Human-Rights Issues

Biotechnology vaccine regulation raises several important ethical and constitutional questions.

A. Informed consent

Article 20 of Federal Law No. 323-FZ establishes the general framework for informed voluntary consent to medical intervention.

A patient should receive appropriate information about:

The nature of the vaccine.

Expected benefits.

Potential adverse reactions.

Medical contraindications.

Available alternatives, where applicable.

B. Medical experimentation

Article 21 of the Russian Constitution prohibits medical, scientific and other experiments involving a person without voluntary consent.

This provision is particularly relevant to clinical investigations of experimental vaccine platforms.

C. Genetic and biological information

Biotechnology vaccine research may involve genetic and biological information.

The processing of personal data is governed principally by Federal Law No. 152-FZ of 27 July 2006, On Personal Data.

Research institutions and manufacturers must consider confidentiality, lawful processing, data security and applicable consent requirements.

D. Vaccine equality and accessibility

Government vaccine programmes also raise questions about equal access, geographical distribution, affordability and discrimination.

A regulatory system must consider whether innovative vaccines are accessible to different population groups, including people living in remote regions.

12. Regulatory Challenges in Russia

Several challenges affect the governance of biotechnology vaccine platforms.

Regulatory challengeLegal concern
Rapid vaccine developmentAdequacy of clinical evidence
New mRNA technologiesQuality and stability
Viral-vector manufacturingBiological safety
Recombinant proteinsAntigen purity and consistency
Emergency registrationRegulatory safeguards
Vaccine injuryCausation and compensation
International licensingPatent and trade-secret disputes
Cross-border distributionEAEU regulatory compliance
Clinical-trial dataTransparency and reliability
Cold-chain failuresProduct quality and liability

Major governance problems

1. Scientific uncertainty: New vaccine platforms can produce uncertainties that require continuous monitoring.

2. Regulatory transparency: Public confidence depends partly on access to reliable clinical evidence and understandable safety information.

3. Manufacturing accountability: Manufacturers must maintain quality throughout the entire production lifecycle.

4. Intellectual-property conflicts: Patent ownership and technology-transfer disputes can affect production capacity.

5. International regulatory cooperation: Differences between national and EAEU requirements can create compliance challenges for manufacturers exporting vaccines.

13. Suggestions for Legal and Regulatory Reform

Several reforms could strengthen Russian biotechnology vaccine governance.

Establish clearer platform-specific technical guidance for mRNA, viral-vector and recombinant vaccines.

Improve transparency concerning clinical-trial results and adverse-event reporting.

Strengthen independent manufacturing inspections.

Develop clearer procedures for vaccine injury assessment and compensation.

Improve regulatory oversight of genetic stability and biological contamination.

Strengthen informed-consent procedures.

Improve coordination between Russian regulators and EAEU institutions.

Establish clearer accountability standards for AI-assisted vaccine development.

Improve long-term monitoring of vaccine effectiveness and safety.

Strengthen international scientific collaboration and responsible technology transfer.

14. Conclusion

Biotechnology Vaccine Platform Regulation in Russia is governed by a combination of pharmaceutical legislation, immunoprophylaxis legislation, constitutional protections, sanitary regulations and EAEU pharmaceutical standards.

Federal Law No. 61-FZ provides the principal framework for medicinal-product registration, clinical investigations, manufacturing and pharmacovigilance. Federal Law No. 157-FZ regulates immunoprophylaxis, while Federal Law No. 323-FZ protects patient rights and establishes informed-consent requirements.

Russian judicial decisions, particularly Constitutional Court decisions Nos. 1867-O (2013), 2759-O (2023), 2187-O (2024) and 83-O (2025), demonstrate how vaccination policies interact with constitutional rights, employment obligations and public-health protection.

The central legal challenge is ensuring that scientific innovation does not undermine patient autonomy, pharmaceutical quality, regulatory accountability or public confidence.

A sustainable regulatory framework must therefore combine scientific evidence, transparent approval procedures, responsible manufacturing, effective pharmacovigilance and constitutional protection.

15. Important Legal Sources and Research References

For further academic research, the following primary legal materials are particularly useful:

Constitution of the Russian Federation, Articles 20, 21, 41, 44 and 55.

Federal Law No. 61-FZ of 12 April 2010 – On Circulation of Medicines.

Federal Law No. 157-FZ of 17 September 1998 – On Immunoprophylaxis of Infectious Diseases.

Federal Law No. 323-FZ of 21 November 2011 – On the Fundamentals of Health Protection of Citizens.

Federal Law No. 52-FZ of 30 March 1999 – On the Sanitary and Epidemiological Well-Being of the Population.

Federal Law No. 152-FZ of 27 July 2006 – On Personal Data.

Civil Code of the Russian Federation, Part IV – Intellectual Property.

Labour Code of the Russian Federation, Article 76.

EAEU Agreement of 29 May 2014.

EAEU Good Manufacturing Practice and pharmacovigilance requirements.

Useful research portals:

Official Russian Legal Information Portal

Consultant Plus – Russian legislation and judicial decisions

Garant – Russian legal database

WIPO Lex – Intellectual Property Legislation

Eurasian Economic Commission

The registration provisions of Federal Law No. 61-FZ and its clinical-trial provisions are available through WIPO Lex's English-language legislative text. The vaccination-related judicial decisions discussed above can be further examined through the cited

Covid-19 Litigation+3

.

 

Academic note: For litigation or publication, verify the current consolidated statutory text and the full Russian-language judicial decisions. The cases discussed here principally establish general vaccination and public-health principles, rather than platform-specific technical approval precedents.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT